Breast Neoplasms Clinical Trials in Stony Brook, New York

3 studies are recruiting for breast neoplasms in Stony Brook, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Stony Brook University Medical Center, Stony Brook, New York
    Locations
    202 in total
    Run by
    BioNTech SE

    See if you can join NCT07173751 on ClinicalTrials.gov

  2. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Stony Brook University-Cancer Center ( Site 0034), Stony Brook, New York
    Locations
    259 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312176 on ClinicalTrials.gov

  3. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

    The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Stony Brook Cancer Center, Stony Brook, New York
    Locations
    49 in total
    Run by
    Natera, Inc.

    See if you can join NCT07214532 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.